Banner

Type 1 interferon (IFN-1) has become an increasingly important biomarker for rheumatologists and lupus patients. We compiled a list of the 34 oral and poster presentations featuring IFN-1 at ACR 2023. This demonstrates the mounting evidence of its utility in managing patients and therapies. DxTerity wishes you a productive and fun conference!

Systemic Lupus Erythematosus (SLE or lupus) is a complex autoimmune disease that is often difficult to manage. An individual’s genomic activity can influence disease progression and response to standard therapy. Lupus research is revealing new drug targets and enabling the development of targeted therapies that may benefit distinct groups of patients. Anifrolumab is one of the newest treatments targeting an important regulatory family of proteins central to immune defense against viruses, Type-1 interferons (IFN-1).¹